Monopar Therapeutics (MNPR, ≈$0.5B mkt cap) and Eton Pharmaceuticals (ETON, ≈$1.6B) both filed Q1 2026 10-Qs on May 14, 2026. Both depend on Wilson disease economics for their thesis. The filings tell opposite stories — and the divergence has been carried, identifiably, across three consecutive quarters.

What the filings say

MNPR. ALXN1840 (bis-choline tetrathiomolybdate), in-licensed from AstraZeneca for ≈$10M cash + 387K shares after AZ took a $244M impairment in 2023. Phase 3 complete (n=255 pooled efficacy, 961-day median follow-up).

The Q1 2026 10-Q MD&A is verbatim identical to the 10-K from March 27, 2026: "encouraged continued dialogue with us on certain questions before we submit our NDA... currently expect to submit our NDA in mid-2026." Note 9 (Subsequent Events): clean. No NDA filed as of May 14, 2026. R&D +112% YoY ($3.49M vs $1.64M) — NDA prep ramp. Cash $137.5M liquid, $2.9M liabilities, runway "at least through December 31, 2027." New wet lab at Rosalind Franklin University Bioscience Incubator (March 22, 2026, $875/month) — physical CMC work. Risk factors unchanged.

Sublicense economics now explicit (previously redacted): 35-45% of any sublicense income to Alexion; 10-20% royalties on net sales; up to $94M in milestone payments.

New post-10-K data presented at AAN April 19, 2026: Phase 3 FoCus sub-analysis in patients with neurological symptoms at baseline (n=77 ALXN1840 vs n=35 SoC). Neurologic worsening at Week 48: 25% SoC vs 9% ALXN1840 (p=0.038). ICGI-S improvement: 17% vs 61% (p=0.008). CGI-I improvement: 19% vs 47% (p=0.003). Durable benefit over ≈3 years. Zinc — the incumbent maintenance therapy — has no neurological efficacy data.

ETON. Q1 2026 10-Q and earnings call (filed same day; transcript May 15) reiterated identical Q4 2025 strategy: GALZIN growing to ≥800 patients, ET-700 ">$100M peak sales," $500M revenue target by 2030. ET-700 pilot just initiated (36 healthy volunteers); pivotal Q1 2027; launch 2030+.

ETON's filings mention ALXN1840 zero times. Third consecutive filing in denial (Q3 2025, Q4 2025, Q1 2026). Cross-corpus check across 10,628 earnings transcripts confirms no Wilson disease participant has named the program in any narrative.

What the market thinks

                       MNPR        ETON
Price                  $59.27      $30.26
52w range position     40%         89%
RSI                    58.9        75.9
Short interest         36.5%       8.4%
Idiosyncratic var      76.6%       54.1%
1Y momentum            +59.5%      +59.9%
Beta                   1.50        0.82
Analyst consensus      $112.79     (limited coverage)
Options market         none        none

MNPR short interest compressed from ≈66% (March 2026) to 36.5% over ≈6 weeks without an NDA catalyst — partial squeeze unwound, plausibly post-AAN covers. With no options market, market-implied probability must be backed out of price.

Solving for the marginal trader's view at $59.27 against modeled state values (approved-broad ≈$225/share NPV, approved-narrow ≈$75, RTF/CRL ≈$25, major delay ≈$38):

The 14-point gap between marginal-trader-implied and factor-decomposition is the named mispricing. We sit closer to the marginal trader than to analysts — appropriate, given the regulator-side concerns the analyst community tends to underweight.

Why the gap exists

Not "market is wrong." Specific reasons:

Conference data integration lag. The AAN neurological sub-analysis was published four weeks before this filing. The clinical record has been built systematically across four conferences in twelve months (EASL → ANA → AASLD → AAN), each extending the data into a new patient subgroup or endpoint. Small-cap with single-analyst-per-firm coverage means slow re-modeling.

Cross-ticker disproof not synthesized. ETON's $500M-by-2030 thesis assumes zinc remains primary maintenance therapy — structurally incompatible with ALXN1840 broad-label approval. But the cross-corpus check that surfaces ETON's three-quarter silence isn't in standard sell-side templates. ETON's 10-K lists ALXN1840 in mandatory risk factors but management has never discussed it in narrative — fits the "Incumbent Narrative Silence on Disruptor" inverted-signal pattern.

BTD-absence anchors the bear. ALXN1840 has Fast Track + Orphan designations but no Breakthrough Therapy Designation, twelve months post-pivotal. FDA reference classes: BTD with BLA-submitted ≈ 75% approval; FT+Orphan without BTD ≈ 55-65%. BTD absence ≥12 months after pivotal data is a "regulator declining to certify substantial improvement" signal. This is likely why analysts at 61% implied probability sit well above the marginal trader at 22% — analysts model clinical efficacy; the marginal short anchors on BTD absence plus opaque FDA dialogue.

FDA "certain questions" is genuinely opaque. Two consecutive filings carry verbatim language with zero progress narrative. Could be CMC (resolvable in weeks), clinical reanalysis (1-3 months), or new mechanistic study (12-24 months). We do not have better information than the market on this specific question. Cross-corpus check confirms the delay pattern is MNPR-specific, not a sector-wide DOGE/shutdown effect — no other pre-NDA biotech uses MNPR's language across 10,628 transcripts.

Risks, ranked

1. FDA requires new mechanistic study. Worst case from the "certain questions" dialogue. NDA filing beyond 24 months. Stock drifts to cash floor (≈$13-16/share) + delay-state optionality. Range: -40% to -50%.

2. CRL on efficacy or mechanism. FT+Orphan-no-BTD reference class has 35-45% historical failure rate after submission. Stock to cash box plus pipeline residual (≈$18). Range: -60% to -70%.

3. Narrow label restricts commercial value. Approval restricted to chelator-intolerant subset or neurological-predominant population. Peak revenue $100-200M vs $500M-1B. Stock $50-100. Range: -15% to +70%.

4. Royalty/sublicense drag caps M&A premium. Now explicit at 35-45% sublicense + 10-20% royalty. Limits acquirer's path to full economics. Already in price; the incremental damage is bounded.

5. Pair-leg correlation amplifies losses. ETON at RSI 75.9, idio 54.1% (mostly sector beta). Pair structure (long MNPR / short ETON) amplifies wins and losses on correlated approval outcomes; doesn't reduce variance.

Catalysts

What would change our mind

Toward bullish:

• 8-K characterizing FDA "certain questions" as CMC or limited clinical reanalysis — collapses most of the bear-case probability.
• 8-K announcing NDA submission — 39% RTF/CRL probability compresses to ≈17% (acceptance conditional only).
• ETON updates 10-Q narrative or earnings call to address ALXN1840 — closes the cross-ticker disproof window; signal to close the short leg of the pair.

Toward bearish:

• Third consecutive filing carrying "mid-2026" language in Q2 2026 10-Q (filed ~Aug 14) — P(major delay) rises from 25% to 40%+.
• 8-K mentioning "additional clinical work" or "supplementary data" — mechanistic-study scenario activated.
• Insider Form 4 pattern breaks (CFO, CEO, COO stop quarter-end buying) — conviction signal weakens; informed-flow has changed view.
• ETON announces M&A or in-license of competing Wilson disease program — inverts the cross-ticker thesis; short leg becomes risk.

Factor scenario

wilson-disease-competitive-landscape as of 2026-05-16:

Expected return: +28% single-name ($59.27 to ≈$76 weighted). Pair structure (long MNPR / short ETON, dollar-neutral) raises EV to ~+33% by capturing ETON's competitive displacement risk on the same approval states. Annualized volatility ≈100%; outcome distribution bimodal; classical Sharpe inappropriate metric.

Evidence

Memo-level LR: 1.4. Mild bullish. Forward EV positive (+28% single-name, +33% pair-trade) over 12-18 months. Edge concentrated in two identifiable mispricings: (1) ≈14pp gap between marginal-trader-implied and factor-decomposition probability on the NDA approval pathway, (2) ETON pricing of competitive displacement as if ALXN1840 doesn't exist. Doorway state on FDA "certain questions" remains the gating uncertainty; "mid-2026" guidance has 45-90 days to resolve. The single-name long is exposed to the FDA black box; the pair captures the proprietary cross-ticker edge with biotech-sector beta neutralized.